Cor­rect­ed: BeiGene builds out long-term case for Brukin­sa in CLL with three-year fol­low-up da­ta

Ed­i­tor’s note: A pre­vi­ous ver­sion of this sto­ry mis­char­ac­ter­ized over­all sur­vival da­ta from the ALPINE study as hav­ing “missed” sta­tis­ti­cal sig­nif­i­cance and over­stat­ed the end­point’s im­por­tance with­in the con­text of chron­ic lym­pho­cyt­ic leukemia. This sto­ry has been up­dat­ed and cor­rect­ed. 

SAN DIEGO — BeiGene tout­ed longer fol­low-up da­ta for its can­cer drug Brukin­sa in re­lapsed or re­frac­to­ry chron­ic lym­pho­cyt­ic leukemia Sat­ur­day, show­ing con­tin­ued im­prove­ments in pro­gres­sion-free sur­vival com­pared to Ab­b­Vie and J&J’s Im­bru­vi­ca.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Venture & Research Associate

Alexandria Real Estate Equities

San Francisco, CA, USA